乐普医疗：植入式脑深部神经刺激器预计近期获批上市 明年有望贡献收入

Core Viewpoint - Lepu Medical (300003) is expected to receive approval for its Deep Brain Stimulation (DBS) device soon, which is anticipated to contribute to revenue next year. The company is also preparing to submit its Cardiac Contractility Modulation (CCM) device for approval in the first and second quarters of next year, indicating that the neuroregulation business segment will provide new growth drivers for the company's performance [1] Group 1 - The DBS device is expected to be approved for market launch shortly [1] - The CCM device is planned for submission in the first and second quarters of next year [1] - The neuroregulation business segment is projected to enhance the company's performance growth [1] Group 2 - The company is focusing on developing implantable medical devices with higher technological barriers and better market competition in response to the centralized procurement environment [1] - This strategy aims to mitigate the impact of centralized procurement policies on the company's business [1]